Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment

Wolfgang N. Löscher1 · Eva-Maria Oberreiter1 · Marcus Erdler2 · Stefan Quasthoff3 · Valeriu Culea3 · Klaus Berek4 · Norbert Embacher5 · Susanne Grinzinger6 · Isolde Hess7 · Franz Stefan Höger8 · Corinne G. C. Horlings1 · Michael Huemer9 · Julia Jecel10 · Waltraud Kleindienst6 · Eva Laich11 · Petra Müller12 · Dierk Oel12 · Wolfgang Örtl13 · Eva Lenzenweger14 · Jakob Rath17 · Klaus Stadler12 · Karl Stieglbauer15 · Claudia Thaler-Wolf16 · Julia Wanschitz1 · Fritz Zimprich17 · Hakan Cetin17 · Raffi Topakian12

Received: 31 August 2018 / Revised: 17 September 2018 / Accepted: 18 September 2018 / Published online: 26 September 2018
© The Author(s) 2018

Abstract
Background and objectives Multifocal motor neuropathy (MMN) is a rare neuropathy and detailed descriptions of larger patient cohorts are scarce. The objective of this study was to evaluate epidemiological, clinical, and laboratory features of MMN patients and their response to treatment in Austria and to compare these data with those from the literature.

Methods Anonymized demographic and clinical data about MMN patients until 31.12.2017 were collected from registered Austrian neurologists. Exploratory statistics on clinical and laboratory features as well as treatment regimens and responses were performed.

Results 57 Patients with MMN were identified, resulting in a prevalence of 0.65/100,000. Mean age of onset was 44.1 ± 13.1 years, the diagnostic delay 5.5 ± 8.4 years. In 77% of patients, symptom onset was in the upper limbs, and in 92%, it occurred in distal muscles. Proximal onset was never observed in the lower limbs. At the final follow-up, the majority of patients had atrophy (88%) in affected regions. Definite motor conduction blocks (CB) were found in 54 patients. Anti-GM1-IgM antibodies were present in 43%. Treatment with intravenous immunoglobulins improved muscle strength and INCAT score initially, but at last follow-up, both scores deteriorated to values before treatment.

Discussion The findings of the present study corroborate the previous findings in MMN. Onset typically occurs in the upper limbs and mostly distal, CBs are found in the majority of cases, while anti-GM1-IgM antibodies are detected in only approximately 40%. Our study underlines that the initial good response to treatment fades over time.

Keywords Multifocal motor neuropathy · Conduction block · Intravenous immunoglobulin · Anti-GM1 antibody

Introduction

Multifocal motor neuropathy (MMN) was first described 30 years ago as a pure motor neuropathy in patients originally diagnosed as lower motor neuron disease [1, 2]. The hallmark in these cases was motor conduction blocks and antibodies directed against GM1 gangliosides and that some patients responded to treatment with cyclophosphamide [2]. Later, the response to treatment with intravenous immunoglobulin (IVIG) was described and several smaller randomized controlled trials demonstrated its effectiveness [3–7], while other treatments were rarely effective and only described in case reports. In addition, due to the rarity of the disease, only a few larger cohort studies, including 88 [8], 80 [9], 47 [10], and 46 [11] patients, described various clinical phenotype, antibody status, electrophysiological findings, and long-term response to treatment. Therefore, we attempted to review all MMN patients in Austria to study the epidemiological, clinical, and laboratory features and the actual short- and long-term response to treatment in form of a nationwide study.
Methods

All registered Austrian neurologists were contacted via mail by the Austrian Neurological Society and asked whether they currently manage patients with MMN. In addition, Austrian neuromuscular centres were specifically contacted. Neurologists and centres were asked to provide a set of anonymized epidemiological, clinical, and laboratory data of their patients: age at symptom onset, age at diagnosis, frequency and location of conduction block, anti-GM1 IgM antibody status, site of onset of weakness, and strength (MRC grade) of the weakest muscle and inflammatory neuropathy cause and treatment disability scale (INCAT score) for arms and legs [12]. The INCAT score ranges from 0 (no impairment) to 5 (inability to use either arm for any purposeful movement or restricted to wheelchair). Strength and INCAT score were recorded at the time of diagnosis, after three treatment cycles and at the last follow-up. Dosing of IVIG was recorded at start of treatment and at the last follow-up. In addition, treating clinicians were asked to provide a clinical global impression (CGI) after 3 months of treatment and at the last follow-up rating the patients’ clinical status to that before treatment as “improved, unchanged or worsened”.

Statistics

Exploratory data analysis was performed and mean ± SD or median and range are given as appropriate. MRC grades and INCAT scores at diagnosis were compared with those after three treatment cycles and at the last follow-up using Friedman analysis, and post-hoc comparisons were made using Bonferroni corrected Wilcoxon test (corrected \( P < 0.017 \)). The influence of diagnostic delay, CB, and GM1-antibody status on muscle strength and INCAT score was analysed using multiple linear correlation analysis. Treatment duration was correlated with muscle strength and INCAT score using Spearman rank correlations. Statistics were only computed for the upper limbs because of the limited number of patients with symptoms in the legs. Statistical analyses were performed using IBM SPSS Statistics, V.24 (IBM, Amrok, New York, USA).

Results

57 MMN patients were identified in the present survey, and 39 (68%) of whom were male. This results in a male:female ratio of 2.2:1 and a calculated point prevalence of 0.65/100,000 (01.01.2017; https://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/bevoelkerung/bevoelkerungsstand_und_veraenderung/bevoelkerung_zu_jahres_quartalsanfang/index.html). Mean age of onset was 44.1 ± 13.1 years, median 45, and range 15–73 years and did not differ between males and females. Based on recent diagnostic criteria [13], 47 (82%) had definite, 7 probable, and 3 possible MMN. Symptom onset was in the upper limbs in 77% and in distal muscles in 92% (Table 1); no patient reported a proximal onset in the lower limbs. In 88% of the patients, muscle atrophy was observed at the last visit (Table 1). Cranial nerve involvement was found in two patients (3.5%), and involved exclusively the hypoglossal nerve. At time of diagnosis, weakness in the arms was usually severe and was less than MRC 4 in 86.3% (Fig. 1a). In the legs, 61.8% had MRC of less than 4. Similarly, INCAT scores were 2 or more in 89.9% of upper limbs (Fig. 1b) and 66.7% in lower limbs.

Conduction blocks (CB) were found in 54 patients; definite CB in 47 and probable CB in 7 patients. CB were seen in the upper limbs in 51 (89.5%) and in the lower limbs in 12 patients (21%). In 3 pts, CB was only seen in the lower limbs. More detailed results are shown in Table 2. Results of IgM-Anti-GM1 antibodies were available for 56 pts, and antibodies were present in 24 (43%).

The diagnostic delay was 5.5 ± 8.4 years, with a median of 3.0 and a range of 0.25–48 years. Time to diagnosis shifted significantly over time (Spearman \( r = 0.720, P < 0.000 \); Fig. 2). Multiple linear regression analysis revealed that diagnostic delay was significantly associated with lower strength in the arms (\( t = -2.165, P < 0.05 \)), while the presence of CB (\( t = 1.262; n.s. \)) and the GM1-antibody status (\( t = 0.024; n.s. \)) was not correlated with MRC grade. Multiple linear regression analysis of diagnostic delay, GM1-antibody status, and CB vs. INCAT score was not significant.

Following diagnosis, 53 patients (93%) received treatment with IVIG. At the last follow-up, 46 patients were still treated, 41 receiving IVIG, and 5 were switched to subcutaneous immunoglobulin (SCIG). These patients were treated for 7.47 ± 5.25 years (median, 7 years; range 1–24 years). IVIG dosing is presented in Table 3. Calculating the mean IVIG dose per year showed a decrease of yearly IVIG dose (first year estimate: 16.3 g/kg/year; last year estimate 10.8 g/kg/year).

| Clinical characteristics | Upper limb onset | Lower limb onset |
|--------------------------|------------------|------------------|
| \( n \)                   | 44               | 13               |
| Distal onset (\( n \))    | 40               | 13               |
| Proximal onset (\( n \))  | 4                | 0                |
| Weakness at time of diagno- | 3 (0–4.5)       | 3 (1.5–4.5)      |
| sis (MRC; mean, range)    |                  |                  |
| Atrophy at last visit (\( n \)) | 40             | 10               |
There was a significant change of upper limb muscle strength with treatment duration ($\chi^2 = 19.851852; \, df = 2; \, P < 0.001$); IVIG improved strength initially ($Z = -4.419; \, P < 0.001$), but MRC grades deteriorated afterwards, and at the last follow-up, they were similar to those before treatment ($Z = -0.769; \, n.s.$) (Fig. 1a). The same was true for the upper extremity INCAT score, which also significantly changed over time ($\chi^2 = 12.612; \, df = 2; \, P = 0.002$); the INCAT score improved significantly after the initial treatment period ($Z = -3.579; \, P < 0.002$), but returned to baseline values at the last follow-up ($Z = -1.0150; \, n.s.$; Fig. 1b). Treatment
duration did not correlate with changes in muscle strength and INCAT score.

The CGI following initial treatment was “improved” in 33 and “unchanged” in 20 patients. At the last follow-up, fewer patients responded to treatment and 12 actually worsened despite treatment ($\chi^2: -4.26; P<0.001$; Fig. 3). Treatment was stopped in seven patients because of continued worsening in 1, sustained improvement in 1, and stable disease in 5.

Discussion

We performed a nationwide survey of MMN in Austria and identified 57 patients corresponding to a prevalence of at least 0.65/100,000. The prevalence in Austria is, therefore, slightly higher than rates reported from Japan (0.29; [14]), but similar to European results, where a prevalence/100,000 of 0.5 was reported from Southeast England [15] and 0.6 from The Netherlands [8]. However, it can be speculated that the actual frequency in our country is even higher as some patients might not have been reported and others may not have been diagnosed. MMN was more frequent in men than woman, which is also a constant finding in other studies as well [8–11, 16]. Age of onset did not differ between men and women, in contrast to the study of Cats et al. [8] who found an earlier onset in men. Nevertheless, disease onset was in agreement with the majority of studies [9–11, 16]. There was a substantial delay between first symptoms and final diagnosis; however, over time, this diagnostic delay shortened significantly as also observed by Cats et al. [8].

Clinically, MMN affects predominantly distal muscles and the upper limbs. Upper limb onset occurred in 77% and was mostly distal, while onset in the lower limbs was rare and never proximal. Proximal onset in the femoral nerve has only been reported in three patients by Stangel et al. [9], while Cats et al. [8] observed proximal weakness only after disease durations of 20 years or longer. Cranial nerve involvement was as expected very rare and affected only the hypoglossal nerve [16]. In general, the clinical pattern of weakness at onset found in the Austrian cohort is almost identical to all the previous reports of clinical features in larger MMN cohorts [9, 16]. Weakness and disability in the Austrian cohort were severe especially in the upper limbs and patients were weaker [8, 9] and more impaired [9] than those in other series, although there was no difference in time to diagnosis.

Employing established diagnostic criteria [13], the majority had definite MMN (87%). As the previous epidemiological studies did not employ these criteria, only indirect comparisons can be drawn based on the frequencies of patients with definite CB. Cats et al. [8], who basically used the same criteria for CB as included in the EFNS criteria, found a definite CB, which is one requirement for definite MMN, in 81%. Slee et al. [10], using slightly different definitions, found only 49% when using the strictest CB definition. These findings further corroborate the notion that also patients with typical clinical features of MMN, but without CB should be diagnosed as MMN and treated accordingly [17, 18].

When CBs were present, they were in the upper limbs most often detected in the median and ulnar nerves, and in the peroneal nerve in the lower extremity, which can be expected as MMN affects predominantly distal muscles. CBs were also found in the radial and musculocutaneous nerves. As these nerves are not routinely studied in many laboratories, the actual frequency of CB in these nerves, especially the radial nerve, might be higher. Again, these findings are in accordance with the previous reports on the anatomical distribution of nerves with CBs [8, 10, 11, 16, 19]. The location of CBs in upper limb nerves varied in different studies: one found CBs most common in distal segments [10], while another study reported CBs more frequent

---

### Table 3

Dosing of IVIG at the beginning (first three treatment cycles) of treatment and the last follow-up; mean ± SD (median; range)

|                      | Initial $n=53$ | Last follow-up $n=41$ |
|----------------------|---------------|-----------------------|
| **Total IVIG dose/treatment cycle (g/kg)** | 1.76 ± 0.45 (2; 0.4–2) | 1.06 ± 0.54 (2; 0.4–2) |
| **Treatment interval (weeks)** | 5.6 ± 2.1 (5; 2–12) | 5.1 ± (5.7) |

![Fig. 3](image-url) Effects of IVIG treatment on clinical global impression (CGI) after the first three treatment cycles (white bars) and at the last follow-up (black bars)
in the upper segments of the ulnar nerve [8]. Unfortunately, we were unable to assess the nerve segments in which CB were found.

In addition to clinical features and CB, the presence of IgM antibodies against GM1 gangliosides is considered a hallmark of MMN. The reported frequencies of anti-GM1 antibody positive patients vary between 30 and 80% [20, 21]. Most larger case series, however, with the exception of Slee et al. [10] who found antibodies in only 25.5%, reported frequencies of 40–50% [8, 11, 22]. The presence of anti-GM1 antibodies in 43% of patients in our study is, therefore, in line with the previous reports. Due to the different laboratory methods used, titres cannot be given as many laboratories rate these tests as positive or negative only. In addition, antibodies against a mixture of GM1 and galactocerebroside were not tested [22].

Imaging studies [23] gain increasing importance in the diagnosis of MMN and are also included in the supportive EFNS criteria [13]. MRI [24, 25], and more frequently, peripheral nerve ultrasound [26, 27] is used to ascertain the diagnosis of immune-mediated neuropathies. In our series, however, such imaging studies have not been applied in a systematic matter and no conclusions regarding imaging can be drawn.

The majority of patients were treated with IVIG. Over the first three treatment cycles, IVIG was given at a mean dose of 1.76 g/kg/cycle every 5.6 months. As treatment in Austria is typically started with 2 g/kg/cycle, the frequency and dosing of maintenance treatment varied between patients. This has also been observed in a German study [9], who reported a large range of dosing and intervals in their MMN cohort. Treatments were initially repeated every 5.6 weeks, which is surprising as previous controlled [6, 7] and open [28] phase 3 trials repeated IVIG every 4 or even 3 weeks, although at lower doses of 1 g/kg. As the EFNS guidelines recommend that an IVIG maintenance therapy of 1 g/kg every 2–4 weeks or 2 g/kg every 1–2 months [13] treatment of MMN in Austria seems to be within established guidelines. Over time, the IVIG dose per cycle decreased, but in parallel, the frequency increased. When estimating the mean yearly IVIG consumption, our data suggest that less IVIG was given per year over time (first year estimate: 16.3 g/kg/year; last year estimate 10.8 g/kg/year). This is in contrast to the previous studies as Stangel et al. [9] reported stable dosage over 1 year, while others reported an increase in IVIG dose over longer treatment duration [8, 29, 30].

As expected, both muscle strength and INCAT scores showed improvement following initial treatment with IVIG [4, 6, 28–31]. Assessed by clinical global impression, 62% improved and none worsened. In general, initial treatment response is estimated to occur in approximately 80% [20]; however, these numbers vary dramatically. Following 1 year of treatment, Stangel et al. [9], e.g., reported an improvement in the INCAT score of only 24%, while in another study [28], which used higher doses and shorter intervals of IVIG treatment, all patients improved.

In the present study, treatment response was not sustained, INCAT score and strength at the last follow-up were similar to pretreatment values, and CGI showed worsening in 26%, while improvement was sustained in only 37%. It can be argued that this decline resulted from the reduction of yearly IVIG dose. However, several other studies also observed a similar deterioration of MMN response to treatment [29, 32], even with increasing IVIG dose [30]. Only one study reported a sustained response, however, using much larger doses of IVIG as given in other studies [31].

The decline despite treatment possibly occurs after 3–7 years of treatment [30] which is in line with the mean treatment duration of 7.5 years in the present study. However, we could not find a significant correlation of treatment duration with INCAT score or strength, maybe due to small patient numbers and large individual variations of treatment response.

In conclusion, the present nationwide survey of MMN in Austria corroborates the previous reports on the epidemiology, clinical features, and treatment response of MMN. MMN is a rare disorder, which clinically seems to follow a typical pattern of weakness, CBs are found in many, but not all patients, and anti-GM1 IgM antibodies are detected in approx. 40%. IVIG still is the only available treatment, but loses its efficacy in many patients after several years of treatment.

Acknowledgements Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

Compliance with ethical standards

Conflicts of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standard Ethical standards concerning safeguarding patients' protected health information and personal data, in addition to compliance with Austrian ethical laws were strictly adhered to. According to Austrian law ethics committee approval is not required for retrospective anonymized observational studies.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103–107. https://doi.org/10.1002/mus.880110203
2. Pestronk A, Cornblath DR, Ilyas AA et al (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24:73–78. https://doi.org/10.1002/ana.410240113
3. Azulay JP, Blin O, Pouget J et al (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44:429–432
4. Van den Berg LH, Kerkhoff H, Oey PL et al (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatr 59:248–252
5. Federico P, Zochodne DW, Hahn AF et al (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256–1262
6. Hahn AF, Beydoun SR, Lawson V et al (2013) A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18:321–330. https://doi.org/10.1111/jnns.12046
7. Leger JM, Chassande B, Musset L et al (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145–153
8. Cats EA, Van Der Pol W-L, Piersers S et al (2010) Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75:818–825. https://doi.org/10.1212/WNL.0b013e3181f0738e
9. Stangel M, Gold R, Pittrow D et al (2016) Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord 69:1680–1687. https://doi.org/10.1177/1756285616629869
10. Slee M, Selvan A, Donaghy M (2007) Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 69:1680–1687. https://doi.org/10.1212/01.wnl.0000277697.55288.d0
11. Taylor BV, Wright RA, Harper CM, Dyck PJ (2000) Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 23:900–908
12. Merkies ISJ, Schmitz PIM, van der Meché FGA et al (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatr 72:596–601
13. Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15:295–301. https://doi.org/10.1111/j.1529-8027.2010.00290.x
14. Miyashiro A, Matsu N, Shimatani Y et al (2013) Are multifocal motor neuropathy patients underdiagnosed? An epidemiological survey in Japan. Muscle Nerve 49:357–361. https://doi.org/10.1002/mus.23930
15. Mahdi-Rogers M, Hughes RAC (2014) Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 21:28–33. https://doi.org/10.1111/ene.12190
16. Nobile-Orazio E (2001) Multifocal motor neuropathy. J Neurommunol 115:4–18
17. Delmont E, Azulay JP, Giorgi R et al (2006) Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 67:592–596. https://doi.org/10.1212/00000436.51897.20
18. Nobile-Orazio E, Cappellari A, Meucci N et al (2002) Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatr 72:761–766
19. Katz JS, Wolfe GI, Bryan WW et al (1997) Electrophysiologic findings in multifocal motor neuropathy. Neurology 48:700–707
20. Nobile-Orazio E, Gallia F (2013) Multifocal motor neuropathy: current therapies and novel strategies. Drugs 73:397–406. https://doi.org/10.1007/s40265-013-0029-z
21. Vlam L, van der Pol WL, Cats EA et al (2012) Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8:48–58. 10.1038/nrneurol.2011.175
22. Nobile-Orazio E, Giannotta C, Mussel L et al (2014) Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatr 85:754–758. https://doi.org/10.1136/jnnp-2013-305755
23. Jongbloed BA, Haakma W, Goeede HS et al (2016) Comparative study of peripheral nerve MRI and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve 54:1133–1135. https://doi.org/10.1002/mus.25391
24. Echaniz-Laguna A, Dietemann J-L (2011) Neurological picture. Seeing the blocks: MRI of the brachial plexus in multifocal motor neuropathy. J Neurol Neurosurg Psychiatr 82:728–728. https://doi.org/10.1136/jnnp.2010.239210
25. Haakma W, Jongbloed BA, Froeling M et al (2017) MRI shows thickening and altered diffusion in the median and ulnar nerves in multifocal motor neuropathy. Eur Radiol 27:2216–2224. https://doi.org/10.1002/j.1529-8027.2010.00290.x
26. Goedee HS, van der Pol WL, van Asseldonk J-TH et al (2017) Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 88:143–151. https://doi.org/10.1212/WNL.0000000000003483
27. Grimm A, Décard BF, Athanasopoulou I et al (2015) Nerve ultrasound: a multi-center, open-label, 52-week phase 3 trial. J Peripher Nerv Syst 15:295–301. https://doi.org/10.1111/jnns.12268
28. Kuwabara S, Misawa S, Mori M et al (2018) Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: a multi-center, open-label, 52-week phase 3 trial. J Peripher Nerv Syst 15:295–301. https://doi.org/10.1111/jnns.12268
29. Leger JM, Chassande B, Musset L et al (2001) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatr 72:596–601. https://doi.org/10.1136/jnnp-2007-121756
30. Terenghi F, Cappellari A, Bersano A et al (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62:870–880. https://doi.org/10.1212/00000436.015-7648-0
31. Vucic S, Black KR, Chong PST, Cros D (2004) Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63:1264–1269
32. Van Den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH (2002) Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125:1875–1886
Affiliations

Wolfgang N. Löscher1 · Eva-Maria Oberreiter1 · Marcus Erdler2 · Stefan Quasthoff3 · Valeriu Culea3 · Klaus Berek4 · Norbert Embacher5 · Susanne Grinzinger6 · Isolde Hess7 · Franz Stefan Höger8 · Corinne G. C. Horlings3 · Michael Huemer9 · Julia Jecel10 · Waltraud Kleindienst6 · Eva Laich11 · Petra Müller12 · Dierk Oel12 · Wolfgang Örtl13 · Eva Lenzenweger14 · Jakob Rath17 · Klaus Stadel12 · Karl Stieglbauer15 · Claudia Thaler-Wolf16 · Julia Wanschitz1 · Fritz Zimprich17 · Hakan Cetin17 · Raffi Topakian12

1 Department of Neurology, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
2 Department of Neurology, SMZ Ost, Vienna, Austria
3 Department of Neurology, Medical University of Graz, Graz, Austria
4 Department of Neurology, BKH Kufstein, Kufstein, Austria
5 Department of Neurology, St. Pölten University, Sankt Pölten, Austria
6 Department of Neurology, Paracelsus University of Salzburg, Salzburg, Austria
7 Neurological Practice, Salzburg, Austria
8 Department of Neurology, LKH Graz Süd-West, Graz, Austria
9 Department of Neurology, Kardinal Schwarzenberg Hospital, Schwarzach im Pongau, Austria
10 2. Department of Neurology, KH Hietzing, Vienna, Austria
11 Department of Neurology, LKH Steyr, Steyr, Austria
12 Department of Neurology, KH Wels-Grieskirchen, Wels, Austria
13 Department of Neurology, Johannes Kepler-University Linz, Linz, Austria
14 Department of Neurology 2, Johannes Kepler-University Linz, Linz, Austria
15 Neurological Practice, Linz, Austria
16 Neurological Practice, Hall in Tirol, Austria
17 Department of Neurology, Medical University of Vienna, Vienna, Austria